Anti-FRAS1/ FRASRS1 monoclonal antibody

Anti-FRAS1/ FRASRS1 antibody for FACS & in-vivo assay

Target products collectionGo to FRAS1/FRAS1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP0451-Ab-1/ GM-Tg-hg-MP0451-Ab-2Anti-Human FRAS1 monoclonal antibodyHuman
GM-Tg-rg-MP0451-Ab-1/ GM-Tg-rg-MP0451-Ab-2Anti-Rat FRAS1 monoclonal antibodyRat
GM-Tg-mg-MP0451-Ab-1/ GM-Tg-mg-MP0451-Ab-2Anti-Mouse FRAS1 monoclonal antibodyMouse
GM-Tg-cynog-MP0451-Ab-1/ GM-Tg-cynog-MP0451-Ab-2Anti-Cynomolgus/ Rhesus macaque FRAS1 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP0451-Ab-1/ GM-Tg-felg-MP0451-Ab-2Anti-Feline FRAS1 monoclonal antibodyFeline
GM-Tg-cang-MP0451-Ab-1/ GM-Tg-cang-MP0451-Ab-2Anti-Canine FRAS1 monoclonal antibodyCanine
GM-Tg-bovg-MP0451-Ab-1/ GM-Tg-bovg-MP0451-Ab-2Anti-Bovine FRAS1 monoclonal antibodyBovine
GM-Tg-equg-MP0451-Ab-1/ GM-Tg-equg-MP0451-Ab-2Anti-Equine FRAS1 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP0451-Ab-1/ GM-Tg-hg-MP0451-Ab-2; GM-Tg-rg-MP0451-Ab-1/ GM-Tg-rg-MP0451-Ab-2;
GM-Tg-mg-MP0451-Ab-1/ GM-Tg-mg-MP0451-Ab-2; GM-Tg-cynog-MP0451-Ab-1/ GM-Tg-cynog-MP0451-Ab-2;
GM-Tg-felg-MP0451-Ab-1/ GM-Tg-felg-MP0451-Ab-2; GM-Tg-cang-MP0451-Ab-1/ GM-Tg-cang-MP0451-Ab-2;
GM-Tg-bovg-MP0451-Ab-1/ GM-Tg-bovg-MP0451-Ab-2; GM-Tg-equg-MP0451-Ab-1/ GM-Tg-equg-MP0451-Ab-2
Products NameAnti-FRAS1 monoclonal antibody
Formatmab
Target NameFRAS1
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-FRAS1 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species FRAS1/ FRASRS1 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP0451
    Target NameFRAS1
    Gene ID80144,231470,289486,697358,478446,101095653,107131184,100051496
    Gene Symbol and Synonymsbl,E130113P14Rik,FRAS1,FRASRS1,mKIAA1500
    Uniprot AccessionQ86XX4
    Uniprot Entry NameFRAS1_HUMAN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000138759
    Target ClassificationN/A

    The target: FRAS1, gene name: FRAS1, also named as FRASRS1. This gene encodes an extracellular matrix protein that appears to function in the regulation of epidermal-basement membrane adhesion and organogenesis during development. Mutations in this gene cause Fraser syndrome, a multisystem malformation that can include craniofacial, urogenital and respiratory system abnormalities. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Oct 2009].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.